HP
ICPT

HealthInvest Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

HealthInvest Partners’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-183,000
Closed -$2.98M – 16
2021
Q4 		$2.98M Buy
+183,000
New +$3.08M 4.2% 12

Other funds holding ICPT

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HealthInvest Partners's ICPT Position: Q1 2022 in Review

HealthInvest Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2022, closing a stake of 183,000 shares — an estimated $2.98M sold.

HealthInvest Partners first reported a position in ICPT in Q4 2021 and held it in 1 quarter. The position peaked at $2.98M in Q4 2021. 148 funds tracked by Wall St. Rank hold ICPT as of Q1 2022.

  • HealthInvest Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • HealthInvest Partners sold 183,000 Intercept Pharmaceuticals, Inc. shares in Q1 2022, an estimated $2.98M.
  • HealthInvest Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2021 and held it in 1 quarter.
  • HealthInvest Partners's Intercept Pharmaceuticals, Inc. position peaked at $2.98M in Q4 2021.
  • 148 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2022.

Based on HealthInvest Partners's 13F filing for Q1 2022, filed 5 May 2022.